UA93581C2 - средство, которое содержит G-CSF, для профилактики и лечения диабетической периферической невропатии - Google Patents

средство, которое содержит G-CSF, для профилактики и лечения диабетической периферической невропатии

Info

Publication number
UA93581C2
UA93581C2 UAA200904262A UAA200904262A UA93581C2 UA 93581 C2 UA93581 C2 UA 93581C2 UA A200904262 A UAA200904262 A UA A200904262A UA A200904262 A UAA200904262 A UA A200904262A UA 93581 C2 UA93581 C2 UA 93581C2
Authority
UA
Ukraine
Prior art keywords
csf
preventing
peripheral neuropathy
treating diabetic
diabetic peripheral
Prior art date
Application number
UAA200904262A
Other languages
English (en)
Ukrainian (uk)
Inventor
Кьюнг-Cy Ким
Жи-Йонг Жин
Original Assignee
Донг-A Фарм. Ko., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Донг-A Фарм. Ko., Лтд. filed Critical Донг-A Фарм. Ko., Лтд.
Publication of UA93581C2 publication Critical patent/UA93581C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Изобретение касается средства для профилактики и лечения диабетической периферической невропатии, которое содержит гранулоцитарный колониестимулирующий фактор (G-CSF) в качестве активного ингредиента, который способен улучшить скорость нервной проводимости и болевую чувствительность путем регенерации кровеносных сосудов в периферических тканях и реабилитации поврежденных нервных тканей.
UAA200904262A 2006-10-30 2007-10-29 средство, которое содержит G-CSF, для профилактики и лечения диабетической периферической невропатии UA93581C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020060105684A KR100812274B1 (ko) 2006-10-30 2006-10-30 Ｇ-ｃｓｆ를 유효성분으로 하는 당뇨성 말초신경병 예방 및치료제

Publications (1)

Publication Number Publication Date
UA93581C2 true UA93581C2 (ru) 2011-02-25

Family

ID=39344418

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200904262A UA93581C2 (ru) 2006-10-30 2007-10-29 средство, которое содержит G-CSF, для профилактики и лечения диабетической периферической невропатии

Country Status (16)

Country Link
US (2) US20100048869A1 (ru)
EP (1) EP2077852B1 (ru)
JP (1) JP5416589B2 (ru)
KR (1) KR100812274B1 (ru)
CN (1) CN101528251B (ru)
AU (1) AU2007314854B2 (ru)
BR (1) BRPI0718099A2 (ru)
CA (1) CA2667178C (ru)
ES (1) ES2448837T3 (ru)
HK (1) HK1132461A1 (ru)
MX (1) MX2009004646A (ru)
NZ (1) NZ576498A (ru)
PT (1) PT2077852E (ru)
RU (1) RU2448726C2 (ru)
UA (1) UA93581C2 (ru)
WO (1) WO2008054098A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100908628B1 (ko) * 2008-03-21 2009-07-21 한양대학교 산학협력단 Ｇ-ｃｓｆ를 유효성분으로 하는 외상성 말초신경 손상 치료용 조성물
KR20100020125A (ko) * 2008-08-12 2010-02-22 한양대학교 산학협력단 Ｇ-ｃｓｆ를 유효성분으로 하는 신경병증성 통증 예방 또는치료제
KR101032307B1 (ko) 2008-10-02 2011-05-06 전북대학교병원 생체적합성 분자광학영상용 양자점 및 이의 제조방법
JPWO2021075536A1 (ru) * 2019-10-18 2021-04-22
EP4299076A1 (en) * 2021-02-26 2024-01-03 Biozipcode, Inc. Novel method and agent for treating, diagnosing and detecting diabetes and complications

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339071C (en) * 1988-08-24 1997-07-29 Koichiro Tsuji Thrombus control agent
JP3954004B2 (ja) * 1991-12-26 2007-08-08 中外製薬株式会社 脳機能障害による疾患の予防・治療薬
JPH0741429A (ja) * 1993-07-30 1995-02-10 Mitsubishi Chem Corp 神経障害改善薬
JP2003113085A (ja) * 1998-04-23 2003-04-18 Takeda Chem Ind Ltd 神経栄養因子様作用剤
CA2365434A1 (en) * 1999-04-15 2000-10-26 St. Elizabeth's Medical Center Of Boston Angiogenic growth factors for treatment of peripheral neuropathy
DE60103940T2 (de) * 2000-02-29 2005-07-28 Pfizer Products Inc., Groton Stabilisierter Granulozyten-Kolonie-stimulierender Faktor
WO2003022290A1 (fr) * 2001-09-05 2003-03-20 Yamasa Corporation Compositions pharmaceutiques pour traiter la neuropathie diabetique
US7695723B2 (en) * 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7785601B2 (en) * 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
TW200507875A (en) * 2003-04-15 2005-03-01 Chugai Pharmaceutical Co Ltd Remedy for diabetes
CN1321640C (zh) * 2005-09-08 2007-06-20 南京医科大学 苄达赖氨酸在制备治疗糖尿病周围神经病变药物中的应用

Also Published As

Publication number Publication date
ES2448837T3 (es) 2014-03-17
HK1132461A1 (en) 2010-02-26
MX2009004646A (es) 2009-05-22
AU2007314854B2 (en) 2014-01-16
KR100812274B1 (ko) 2008-03-13
US20100048869A1 (en) 2010-02-25
JP5416589B2 (ja) 2014-02-12
BRPI0718099A2 (pt) 2013-11-05
EP2077852A1 (en) 2009-07-15
AU2007314854A1 (en) 2008-05-08
EP2077852A4 (en) 2012-01-18
RU2448726C2 (ru) 2012-04-27
JP2010508265A (ja) 2010-03-18
CA2667178A1 (en) 2008-05-08
PT2077852E (pt) 2014-03-04
WO2008054098A1 (en) 2008-05-08
US20110076247A1 (en) 2011-03-31
CN101528251B (zh) 2013-03-06
RU2009116833A (ru) 2010-12-10
CN101528251A (zh) 2009-09-09
EP2077852B1 (en) 2013-11-27
CA2667178C (en) 2015-12-29
NZ576498A (en) 2012-03-30

Similar Documents

Publication Publication Date Title
EP2133365A3 (en) Compositions and methods for the treatment of infections and tumors
SG158112A1 (en) Hepatocyte growth factor (hgf) binding proteins
NZ608829A (en) Pharmaceutical composition comprising an sglt2-inhibitor, methods for treating and uses thereof
WO2007062078A3 (en) Thrombopoietin activity modulating compounds and methods
WO2007120936A3 (en) Use.of vildagliptin for the treatment of diabetes
EP2594562A3 (en) 2-acylaminopropanol-type glucosylceramide synthase inhibitors
UA101309C2 (ru) Антагонисты активина-actrii и их применение для повышения уровня эритроцитов
EP2275543A3 (en) Compositions and their uses directed to hepcidin
MY152172A (en) Therapeutic agent for diabetes
WO2006128125A3 (en) Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases
WO2005094554A3 (en) Therapeutic agents, methods, and treatments
UA93581C2 (ru) средство, которое содержит G-CSF, для профилактики и лечения диабетической периферической невропатии
IL188176A0 (en) Stable pharmaceutical composition comprising linezolid form iv
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
MX345032B (es) Antagonistas del receptor ep4 para el tratamiento de cáncer.
EP2251013A3 (en) Use of inositol-tripyrophosphate in treating Alzheimer's disease, stroke or osteoporosis
MXPA06012206A (es) Composicion farmaceutica ozonizada y metodos.
WO2007019575A3 (en) Methods for treating b-cell malignancies using taci-ig fusion molecule
TNSN08506A1 (en) Substituted carboxamides
WO2009019708A3 (en) Pharmaceutical compositions and methods for the treatment of cancer
WO2009106555A3 (fr) Gel de sucralfate sterilise
EP1818064A3 (en) Methods of treating skin to enhance therapeutic treatment thereof
WO2006138589A3 (en) Opioid receptor ligands
WO2006020912A3 (en) Treatments for congestive heart failure
WO2009116836A3 (en) Agent comprising g-csf for treatment of traumatic peripheral nerve injury and method for treating traumatic peripheral nerve injury with the same